Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 14/20 | 0.44 |
| ▸ | KDM5B | Q9UGL1 | 6/20 | 0.44 |
| ▸ | KDM2B | Q8NHM5 | 5/20 | 0.44 |
| ▸ | KDM5A | P29375 | 5/20 | 0.44 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | DCTPP1 | Q9H773 | 2/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6487673 | 0.92 | JMJD6 (0.41) | KDM4CKDM5BKDM2BKDM5ADCTPP1 | |
| SCHEMBL6488966 | 0.89 | RXRA (0.41) | DCTPP1 | |
| SCHEMBL6494714 | 0.89 | KDM4C (0.44) | KDM4CKDM5BKDM2BKDM5AKMO | |
| SCHEMBL6488103 | 0.88 | P4HTM (0.40) | DCTPP1 | |
| SCHEMBL6488456 | 0.88 | DCTPP1 (0.44) | DCTPP1 | |
| SCHEMBL6489353 | 0.85 | PIK3C2B (0.38) | DCTPP1NTRK1 | |
| SCHEMBL6489346 | 0.82 | MRGPRX4 (0.46) | — | |
| SCHEMBL6489130 | 0.82 | MAPT (0.40) | DCTPP1 | |
| SCHEMBL6491045 | 0.82 | DCTPP1 (0.42) | DCTPP1 | |
| SCHEMBL6497678 | 0.82 | PTPN11 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | KDM4C 443/4885KDM5B 551/4885KDM2B 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.